Oct 07, 2025 Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings View PDF
Dec 03, 2024 Resalis Therapeutics Announces Initiation of Phase 1 Clinical Trial for RES-010 in Obesity View PDF
Oct 28, 2024 Resalis Therapeutics Gains Strategic Equity Investment from Sanofi View PDF
Feb 1, 2024 Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer View PDF
Jan 4, 2024 Resalis Therapeutics Raises €10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity View PDF
Feb 22, 2023 Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases View PDF
